R&D Spotlight:
Precision Neuroscience: Biomarkers And Patient Stratification
Precision Neuroscience: Biomarkers And Patient Stratification
SPONSORED BY
Discover the latest approaches to precision neuroscience through biomarker development and patient stratification.
Explore fluid, digital and imaging biomarkers and how these approaches can support disease characterisation, patient selection and therapeutic development across CNS disorders. This focused online showcase brings together industry experts to examine practical strategies for developing and applying biomarkers to enable more targeted approaches to CNS drug development and precision medicine.
- Advance CNS Biomarkers – Explore fluid biomarkers across plasma and CSF alongside digital and imaging biomarkers for improved disease characterisation
- Improve Patient Stratification – Gain insights into using biomarker strategies to identify and stratify patient populations more effectively
- Enable Precision Neuroscience – Examine how integrated biomarker approaches can support precision medicine and more targeted CNS drug development
VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:
- CNS Biomarker Development
- Neuroscience
- Precision Medicine
- Patient Stratification
- Translational Medicine
- Clinical Development
- Digital Biomarkers
- Imaging Biomarkers
- Fluid Biomarkers
- Bioinformatics
- CNS Drug Development
60-Minute Agenda
Industry Presentation
Industry Presentation
Solution Provider Presentation
Panel Discussion
End of Technology Showcase
About 10x Genomics
10x Genomics builds technologies that turn biology into answers, giving researchers the resolution to see how diseases develop and respond to treatment.
Its Chromium Single Cell platform delivers single cell multiomics across thousands of samples and billions of cells, even from FFPE, while its spatial portfolio spans Atera In Situ, Xenium In Situ, and Visium Spatial for whole transcriptome insight at subcellular resolution.
Newer additions like Flex Apex and Atera push sample access and throughput further still, profiling FFPE and fixed whole blood and running up to 800 whole transcriptome samples per year. This work powers breakthroughs across pharma, oncology, immunology, and AI cell models, and has been cited in over 10,000 publications by scientists advancing their research worldwide.
